NEWS

Granted reimbursement of the Silk+ flow diverter on the French market

Balt is thrilled to announce today, the Silk+ reimbursement has been granted on the French market.

COVI-LINNC roundtable: government and hospital strategies

COVI-LINNC roundtable: lack of some drugs in the ICU

COVI-LINNC roundtable: epidemic situation in France

COVI-LINNC roundtable: Patient regulation and testing

Device performance evaluated: extensive in vitro testing of the CascadeT...

The CascadeTM Non-Occlusive Remodeling Net (Perflow Medical, Israel) is an innovative fully retrievable neck-bridging temporary support device designed for use during coil embolisation of intracranial aneurysms which allows for flow within the parent vessel while providing coverage at the neck during coiling of the aneurysm. In this article, the Cascade device was tested in vitro within a variety of aneurysm types and – after 480 attempted coilings – no evidence of coil protrusion either through the mesh wall of the device itself or any coil protrusion into the parent vessel was observed,underlining device viability and effectiveness.

Watch the COVI-LINNC worldwide roundtable!

Multiple aneurysms - Who is the culprit?

Cerus Endovascular Receives CE Mark Approval for its 021 Contour Neurova...

FREMONT, Calif. and OXFORD, England, April 29, 2020 /PRNewswire/ -- Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has received CE Mark approval for its 021 Contour Neurovascular System™, compatible with smaller commercially available 021 microcatheters for the treatment of saccular intracranial aneurysms. The Contour Neurovascular System™ is a unique, fine mesh braid that is deployed across the neck of the aneurysm sac and provides a combination of flow diversion and flow disruption through a single device implant. This new, lower profile system will allow physicians to access more distally challenging vascular anatomies.

Phenox GmbH launches p64 MW Flow Modulation Device with HPC coating tech...

Bochum, Germany – 27 April 2020 - Phenox GmbH, a pioneer of innovative technologies for neurovascular diseases, has announced the European launch of the new p64 MW Flow Modulation Device. The device received CE mark in January 2020 and is available with the proprietary HPC surface modification, a new technology which could revolutionize patient care in vascular intervention.